For the Inventor, By the Inventor

Enter assignee name

Sodertalje, Sweden

Astrazeneca Ab

USPTO Granted Patents = 1,500

CIPO Patents = 76

EPO Patents = 375

Trademarks = 147

Forward Citations = 11,606

Loading Chart...

Loading Chart...

2,043 inventors (with patents filed for the assignee):

Roger Victor Bonnert (32 out of 46 patents)

Stephen Connolly (31 out of 31 patents)

Christopher Walpole (29 out of 31 patents)

4. William Brown (27 out of 27 patents)

5. Stephen Thom (26 out of 60 patents)

6. Stefan Berg (25 out of 28 patents)

7. Bernard Barlaam (24 out of 24 patents)

8. Laurent Francois Andre Hennequin (23 out of 38 patents)

9. Ingemar Starke (22 out of 56 patents)

10. Andrew Peter Thomas (22 out of 47 patents)

11. Brian Springthorpe (22 out of 26 patents)

12. Kurt G Pike (22 out of 26 patents)

13. Maurice Raymond Verschoyle Finlay (21 out of 28 patents)

14. Abdelmalik Slassi (21 out of 55 patents)

15. Michael James Waring (21 out of 21 patents)

Core Competencies:

Heart Failure

Dapagliflozin

Non-Small Cell Lung Cancer

IRAK4 Inhibitors

Chronic Kidney Disease

Anticancer Agents

Chimeric Antigen Receptors

Protein Kinase B Inhibitors

Orexin Receptor Modulators

Dendrimer Formulations

5-Lipoxygenase Activating Protein Inhibitors

Homologous Recombination Deficient Cancer

1,500 patents: Sort by Forward Citations

1. 12472194 - Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same (2025-11-18),

2. 12465608 - Osimertinib for use in the treatment of non-small cell lung cancer (2025-11-11),

3. 12465593 - Pharmaceutical composition (2025-11-11),

4. 12453729 - Pharmaceutical formulations (2025-10-28),

5. 12448385 - Substituted indazoles as IRAK4 inhibitors (2025-10-21),

6. 12441744 - 2,6,9-trisubstituted purines (2025-10-14),

7. 12435097 - Arginase inhibitors and methods of use thereof (2025-10-07),

8. 12421208 - Chemical compounds (2025-09-23),

9. 12414954 - POLQ inhibitors (2025-09-16),

10. 12410254 - Treatment of cardiometabolic disease with inhibitors of type I interferon signalling (2025-09-09),

11. 12410187 - Fused tricyclic compounds useful as anticancer agents (2025-09-09),

12. 12409186 - Methods of treating chronic kidney disease with dapagliflozin (2025-09-09),

13. 12409174 - Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases (2025-09-09),

14. 12377164 - Linkers and conjugates (2025-08-05),

15. 12364689 - Dosage regimen for the treatment of cancer (2025-07-22),

AstraZeneca AB is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. They aim to improve the health and wellbeing of people around the world. AstraZeneca AB is committed to addressing some of the world's most pressing health challenges, such as cancer, cardiovascular diseases, respiratory diseases, and more. With innovative research, AstraZeneca AB strives to provide effective and accessible treatments to patients everywhere.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

1,500 Patents

#1 in Sodertalje

#3 in Sweden

#642 in the World

Sodertalje, Sweden

Astrazeneca Ab

Forward Citations = 11,606

2,043 inventors:

Roger Victor Bonnert (32 out of 46 patents)

Stephen Connolly (31 out of 31 patents)

Christopher Walpole (29 out of 31 patents)

4. William Brown (27 out of 27 patents)

5. Stephen Thom (26 out of 60 patents)

Please report any incorrect information to support@idiyas.com

Loading…